Clinuvel Has Done Its Reimbursement Homework For Orphan Drug Scenesse, But Can It Make Money?
This article was originally published in The Pink Sheet Daily
Executive Summary
As Australia-listed Clinuvel prepares to file its porphyria drug in Europe, it’s confident the orphan treatment will win reimbursement. But the firm will have to exploit larger indications like vitiligo in order to provide a return for investors.